key: cord-0720258-7v9zpd78
authors: Chen, Liting; Wang, Gaoxiang; Long, Xiaolu; Hou, Hongyan; Wei, Jia; Cao, Yang; Tan, Jiaqi; Liu, Weiyong; Huang, Liang; Meng, Fankai; Huang, Lifang; Wang, Na; Zhao, Jianping; Huang, Gang; Sun, Ziyong; Wang, Wei; Zhou, Jianfeng
title: Dynamics of Blood Viral Load is Strongly Associated with Clinical Outcomes in COVID-19 Patients: A Prospective Cohort Study
date: 2020-10-26
journal: J Mol Diagn
DOI: 10.1016/j.jmoldx.2020.10.007
sha: b056dbf635378cb966156b9a870a0bac218cb921
doc_id: 720258
cord_uid: 7v9zpd78

The prevalence and clinical relevance of viremia in patients with coronavirus disease 2019 (COVID-19) are not well-studied. A prospective cohort study was designed to investigate blood viral load and clearance kinetics in 52 patients (median age, 62 years; 31 [59.6%] male) and explore their association with clinical features and outcomes based on a novel one-step reverse-transcription droplet digital PCR (RT-ddPCR). By using one-step RT-ddPCR, 92.3% (48/52) of this cohort was quantitatively detected with viremia. The concordance between the blood and oropharyngeal swab tests was 60.92% (53/87). One-step RT-ddPCR was tested with a 3.03% of false positive rate and lower 50% confidence interval of detection (LOD(50)) at 54.026 copies/ml plasma. In all critical patients, the blood viral load was not eliminated, while the general and severe patients showed similar ability to clear the viral load. The viral loads in critical patients were significantly higher than those in general and severe counterparts. Among the 52 patients, 30 (58%) were discharged from hospital. Among half of 30 discharged patients, blood viral load remained positive, of which 76.9% (10/13) completely cleared their blood viral load at follow-up. Meanwhile, none of their close contacts had the evidence of infection. Quantitative determination of blood viral test is of great clinical significance to the management of COVID-19 patients.

The end of 2019 witnessed an outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and its associated coronavirus disease 2019 in Wuhan, China (1). By April 3, 2020, more than 1,000,000 cases have been confirmed, and among them over 50,000 died worldwide. Its rapid global spread has led to subsequent declaration of a pandemic by the World Health Organization (2) . Currently, a great many clinical challenges concerning COVID-19 need to be addressed urgently. Mounting evidence has shown that, the SARS-CoV-2 test of respiratory specimens turned positive for the virus after discharge (3) which rises the concerns about the possible transmission via these patients.

To improve SARS-CoV-2 testing sensitivity, researchers tried different sampling locations. Peripheral blood should be theoretically an ideal sampling input for viral test since it contains a variety of biomarkers shed from the whole body, including cell-free DNA (cfDNA) and RNA (cfRNA), et al (4) . Despite the critical clinical importance of viremia in pathogenesis and progression of COVID-19 (5), so far, only two studies examined the viral load in peripheral blood but the result was unsatisfactory due to limited sensitivity of real-time PCR (6) . The prevalence and clinical significance of viremia in patients with COVID-19 are unknown. Recently, two studies had shown that droplet digital PCR (ddPCR), possesses much higher sensitivity and specificity than conventional traditional real-time PCR in SARS-CoV-2 test of respiratory specimens (7) , which provides the possibility for studying the prevalence and clinical significance of viremia in COVID-19 patients. Furthermore, many evidences had proposed that one-step RT-droplet digital PCR (RT-ddPCR) proved to be more precise and fully amenable to the viral RNA absolute quantification, especially when RNA J o u r n a l P r e -p r o o f concentration was low (8) .

In this prospective cohort study, we developed a novel test for quantitative and dynamic assessment of the blood viral load of SARS-CoV-2 and validated it in 52 cases of confirmed COVID-19. By using this method, we attempted to study the prevalence and clinical significance of viremia in COVID-19 patients. 

Between January 30 to February 26, 2020, 52 patients with COVID-19 were enrolled into this prospective study after screening (Supplemental Figure S1 ). The diagnosis and the illness severity of COVID-19 were defined according to the Chinese management guideline for COVID-19 (version 7.0) (https://www.who.int/docs/default-source/wpro---documents/countries/china/covid-19-briefin g-nhc/1-clinical-protocols-for-the-diagnosis-and-treatment-of-covid-19-v7.pdf March 2020) and the World Health Organization interim guidance (9) . Methods for laboratory confirmation of SARS-CoV-2 infection have been described elsewhere (10) . Exclusion criteria included: (1) no clinical and chest radiographic findings were available; (2) no written informed consent could be obtained; (3) patients had received remdesivir or were involved in other clinical J o u r n a l P r e -p r o o f trials.

Specimens and data of the enrolled participants were collected prospectively according to study design (Supplemental Figure S1 ). The first and the third day after the enrollment were designated D 1 and D 3 , respectively. D x referred to the day when disease progressed according to the Chinese management guideline for COVID-19 (version 7.0). Dend was the day before discharge or the death. A patient had to meet the following criteria to be deemed clinically cured and eligible for discharge: (1) body temperature remained normal for more than 3 days;

(2) respiratory symptoms resolved; (3) chest CT showed substantial improvement of acute exudative lesions; (4) two consecutive real-time PCR assays, at least 24 h apart, yielded negative results. Patients' data were entered into an electronic data capture system (EDCS), including demographics, medical history, daily clinical findings, oximetric measurements and J o u r n a l P r e -p r o o f laboratory data, involving complete blood count, serum biochemical parameters, high sensitivity C-reactive protein (hsCRP), serum interleukin-6 (IL-6), IL-8 and ferritin and treatments they received.

The patients were followed up by post-discharge clinic visit. The close contacts of the patients, who were eligible for discharge but were positive for plasma SARS-CoV-2, were also included for clinical and laboratory examination to rule out possible transmission by the patients.

For quantitative detection of SARS-CoV-2 copies number, Viral RNA purification kit Table S1 ). To test the quantitative capacity, SARS-CoV-2 plasmid standards (Sangon Biotech, Shanghai，China) were linearized by restriction enzyme BamHI , five-fold serially diluted at the concentrations ranging from approximately 50000 J o u r n a l P r e -p r o o f copies/µl to 16 copies/µl and subjected to ddPCR amplification. To evaluate the lower limit of detection, which were defined as the lower 50% confidence interval of detection (LOD 50 ), plasma samples from patient DF were used as standards (11) . Plasma samples from 33 healthy donors served as negative control to estimate the false positivity in healthy samples of the test.

The SARS-CoV-2-specific IgM and IgG were detected by paramagnetic particle chemiluminescent immunoassay (CLIA) using iFlash-SARS-CoV-2 IgM/IgG assay kit (SHENZHEN YHLO BIOTECH CO., LTD., Shenzhen, China) and iFlash Immunoassay

Analyzer (SHENZHEN YHLO BIOTECH CO., LTD.，Shenzhen， China).

Categorical variables were presented as frequency and proportions. Mean ± standard deviation is given for continuous variables, median and ranges are given for variables that 

The study included 52 patients with COVID-19 and their data are summarized in 

We developed a SARS-CoV-2 detection system based on RT-ddPCR. Linearized plasmids with ORF1ab inserted were serially diluted and used as standards to test the quantitative capacity of the system. Each concentration, measured in triplicate, was well in line with expected concentration (R 2 = 0.998, P < 0.001), indicating that ddPCR using the probe-primer set for SARS-CoV-2 could accurately quantify SARS-CoV-2 copies ( Figure 1A ). Next, a COVID-19 patient DF with severe defect in humoral immunity, was continuously measured for SARS-CoV-2 load in blood and oropharyngeal swabs by using one-step RT-ddPCR. The Figure 1D ).

We 

The average plasma viral load in general, severe and critical patients was 81.68 (0~312.5) copies/ml, 73.62 (0~317) copies/ml and 176 (0~392) copies/ml, respectively ( Figure 3A ).

While the plasma viral load was significantly higher in critical patients than in general and severe patients (P < 0.001), no significant difference was found between the general and severe patients (P = 0.885). In our cohort, disease progression occurred in 2 general (G19 and J o u r n a l P r e -p r o o f G9) and 3 severe patients (S13, S15 and S16) and 4 of the 5 patients concomitantly experienced a substantial increase in the blood viral load ( Figure 3B ). The peak level of anti-IgG of SARS-CoV-2 in critical patients was lower than in general (P = 0.044) and severe (P = 0.011) patients ( Figure 3D ), while no significant difference was found in peak IgM among the three groups ( Figure 3C ). All inflammatory factors including hsCRP, ferritin, sIL6 and sIL8 were profoundly higher in critically ill patients in comparison to all the other patients ( Figure 3E-H) . Interestingly, while hsCRP was significantly higher in severe patients than in general patients, no significant difference was revealed in the levels of ferritin, sIL6

and sIL8, suggesting that other cytokines might be responsible for the increased inflammatory reaction in severe patients.

Among 30 discharged patients, 18 were general patients and 12 were severe patients ( Figure   2 ). At the time when they satisfied the discharge criteria, the blood viral test yielded positive results in 50% (15/30) of the patients. Important indicators, including disease severity, serum antibody level, viral cfRNA copies, time from illness onset to discharge, absolute lymphocyte count and corticosteroid exposure were compared between the positive and negative patients (Supplemental Table S2 ). There were no significant differences in these indicators between the two subgroups (Supplemental Table S2 

In this prospective cohort study, we developed and validated a novel detection method to quantitatively measure the viral load of SARS-CoV-2 in the blood of COVID-19 patients.

Quantitative capacity was evaluated by linearized DNA, within which the reverse-transcriptase step was not included, hence the results were not completely applicable to RNA.

By using this technique, we were able to address the prevalence and clinical significance of viremia in COVID-19 patients. To our knowledge, this is the first report to depict the clearance kinetics of blood SARS-CoV-2 over the entire course of COVID-19. Remarkably, our study, including a protracted follow-up of survivors, suggested that all critical patients failed to eliminate blood viral load. In contrast, the general and severe patients were equally capable of completely clearing the blood viral load. Second, blood viral load was found to be associated with the severity of COVID-19. The viral load was significantly higher in the critical patients than in their general/severe counterparts, which could be, at least partially, ascribed to the impaired capability to generate SARS-CoV-2-specific antibodies on the part of critical patients. Among the patients whose disease deteriorated, a corresponding rise in blood viral load was detected. Interestingly, although there was no significant difference in the level of blood viral load between the general and severe patients, the severe patients showed stronger inflammatory response as defined by hsCRP level. This finding provides a rationale (B) Levels of plasma SARS-CoV-2 cfRNA before and after disease progression were analyzed. Paired t-test showed significance within these two groups.

(C-H) The levels of peak SARS-CoV-2 specific IgM (C), IgG (D), as well as hsCRP (E), peak serum ferritin (F), peak sIL6 (G) and peak sIL8 (H) were compared among general, severe and critical patients. Error bars, mean ± SD. Results were test for significance with Tukey's multiple comparisons test. *, P < 0.05; **, P < 0.01; ***, P < 0.001. A U test was used.

J o u r n a l P r e -p r o o f 

Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia

A Novel Coronavirus from Patients with Pneumonia in China

Covid-19: WHO declares pandemic because of "alarming levels" of spread, severity, and inaction

Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury

SARS-CoV-2 and viral sepsis: observations and hypotheses

Detectable 2019-nCoV viral RNA in blood is a strong indicator for the further clinical severity

Quantitative Detection and Viral Load Analysis of SARS-CoV-2 in Infected Patients

One-step RT-droplet digital PCR: a breakthrough in the quantification of waterborne RNA viruses

Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected: interim guidance

Correlation of Chest CT and RT-PCR Testing for Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases

Relative analytical sensitivity of donor nucleic acid amplification technology screening and diagnostic real-time polymerase chain reaction assays for detection of Zika virus RNA

Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding

Virological assessment of hospitalized patients with COVID-2019

We appreciated eStart Medical Technology. CO., Ltd., Professor Jennifer Hou and Professor Guangliang Shan for discussion and building the electronic data capture system (EDCS).